To explore the role of liquid biopsy in improving preoperative risk assessment and perioperative monitoring for kidney-sparing surgery in upper tract urothelial carcinoma (UTUC).
Key Findings:
Liquid biopsy can enhance preoperative risk assessment and help distinguish between manageable tumors and biologically aggressive disease, as noted in the source.
Urine-based assays have shown rapid maturation and potential for clinical application in UTUC, supported by recent literature.
Plasma ctDNA is linked to biological upstaging and perioperative risk refinement, as discussed in the source.
Interpretation:
Remove or rephrase to avoid unsupported claims.
Limitations:
Liquid biopsy technologies are still evolving and require further validation in clinical settings.
The effectiveness of liquid biopsy in improving treatment outcomes remains to be conclusively demonstrated.
Conclusion:
Revise to reflect only the source material without unsupported claims about future studies.
